parthenolide and staurosporine

parthenolide has been researched along with staurosporine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chiao, P; Su, H; Xiao, Y; Zhong, G; Zhong, Y; Zhou, Z	1
Tallman, M	1

Other Studies

2 other study(ies) available for parthenolide and staurosporine

Article	Year
NF-kappa B activation is not required for Chlamydia trachomatis inhibition of host epithelial cell apoptosis. Journal of immunology (Baltimore, Md. : 1950), 2005, Feb-01, Volume: 174, Issue:3 Topics: Apoptosis; Chlamydia trachomatis; Cycloheximide; Diterpenes; Epithelial Cells; Gene Deletion; HeLa Cells; Humans; Immunity, Innate; NF-kappa B; Sesquiterpenes; Signal Transduction; Staurosporine; Transcription Factor RelA	2005
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11 Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin	2008

Article

Year

NF-kappa B activation is not required for Chlamydia trachomatis inhibition of host epithelial cell apoptosis.

Journal of immunology (Baltimore, Md. : 1950), 2005, Feb-01, Volume: 174, Issue:3

Topics: Apoptosis; Chlamydia trachomatis; Cycloheximide; Diterpenes; Epithelial Cells; Gene Deletion; HeLa Cells; Humans; Immunity, Innate; NF-kappa B; Sesquiterpenes; Signal Transduction; Staurosporine; Transcription Factor RelA

2005

Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.

Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11

Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin

2008